Skip to main content
Top
Published in: International Journal of Diabetes in Developing Countries 1/2024

Open Access 17-02-2024 | Sitagliptin | Original Article

A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial

Authors: Awadhesh Kumar Singh, Rakesh Sahay, Navneet Gil, Sudhir Tripathi, Vipul Khandelwal, Indraneel Basu, Jayashree Shembalkar, Manoj Kumar Srivastava, Girish Bhatia, Vaishali Pathak, Amol Dange, Mayura Chaudhri, Arindam Naskar, Ashish Mondal, Pawan Gangwal, Surendra Kumar, Deepak Kumar, Yandrapati gnana sundara Raju, Sanket Sorate, Onkar Gavli, Sunita Kumbalkar, Deepak Varade, Harshal Chaudhari, Durga Prasad, Manoj Patil, Nikhil Bhagwat, Rohit Agarwal, Arun Pandey, Soumya Ghosh, Shubhashree Patil, Vishal Kini, Akhilesh Sharma, Mayur Mayabhate, Roshan Pawar, Aashish Rajput, Vinakaya Shahavi

Published in: International Journal of Diabetes in Developing Countries | Issue 1/2024

Login to get access

Abstract

Objective

To assess the efficacy and safety of fixed-dose combinations (FDC) of triple-drug dapagliflozin, sitagliptin, and metformin (DSM) compared with FDC of two-drug sitagliptin and metformin (SM), in Indian adult patients with type 2 diabetes (T2D).

Methods

A multicentric, randomized, double-blind, active-controlled, Phase 3 study (CTRI/2021/10/037461) was conducted on 274 Indian adult patients with T2D. Patients were randomized (1:1) to receive either an FDC of triple-drug (n = 137) dapagliflozin propanediol 10 mg, sitagliptin phosphate 100 mg, and metformin hydrochloride 1000 mg extended-release (DSM) or FDC of two-drug (n = 137) sitagliptin phosphate 100 mg and metformin hydrochloride 1000 mg sustained-release (SM), for 16 weeks. The primary endpoint was a change in HbA1c, while the secondary endpoints were changes in fasting plasma glucose (FPG), postprandial glucose (PPG), body weight, and safety.

Results

Both DSM and SM FDCs reduced HbA1c significantly (-1.45% and -1.00%, respectively, both p < 0.0001), however, HbA1c lowering was superior with DSM (∆ -0.45%; p = 0.0005) compared to SM, at week 16. Similarly, both DSM and SM FDCs reduced FPG and PPG significantly, however, FPG (∆ -12.4 mg/dl; p = 0.003) and PPG reduction (∆ -18.45 mg/dl; p = 0.01) were significantly superior to DSM compared to SM, respectively. No significant reduction in body weight was observed between the two arms. Both FDCs were well tolerated.

Conclusion

FDC of DSM was superior to SM in reducing HbA1c, FPG, and PPG in Indian adults with T2D. Both triple and dual FDCs had optimal safety profiles.
Literature
1.
go back to reference Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S, VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519–29.CrossRefPubMed Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S, VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519–29.CrossRefPubMed
2.
go back to reference The GRADE Study Research Group. Glycemia reduction in type 2 diabetes — glycemic outcomes. N Engl J Med. 2022;387:1063–74.CrossRef The GRADE Study Research Group. Glycemia reduction in type 2 diabetes — glycemic outcomes. N Engl J Med. 2022;387:1063–74.CrossRef
3.
go back to reference Singh AK, Singh R, Chakraborty PP. Diabetes Monotherapies versus Metformin-Based Combination Therapy for the Treatment of Type 2 Diabetes. Int J Gen Med. 2021;14:3833–48.CrossRefPubMedPubMedCentral Singh AK, Singh R, Chakraborty PP. Diabetes Monotherapies versus Metformin-Based Combination Therapy for the Treatment of Type 2 Diabetes. Int J Gen Med. 2021;14:3833–48.CrossRefPubMedPubMedCentral
4.
go back to reference DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–95.CrossRefPubMedPubMedCentral DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–95.CrossRefPubMedPubMedCentral
5.
go back to reference Hansen L, Iqbal N, Ekholm E, et al. Postprandial dynamics of plasma glucose, insulin and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy. Endocr Pract. 2014;20:1187–97.CrossRefPubMed Hansen L, Iqbal N, Ekholm E, et al. Postprandial dynamics of plasma glucose, insulin and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy. Endocr Pract. 2014;20:1187–97.CrossRefPubMed
6.
go back to reference Singh AK, Singh R. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences. Expert Rev Clin Pharmacol. 2016;9(2):229–40.MathSciNetCrossRefPubMed Singh AK, Singh R. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences. Expert Rev Clin Pharmacol. 2016;9(2):229–40.MathSciNetCrossRefPubMed
7.
go back to reference Singh AK, Singh A, Singh R. Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials. Endocr Pract. 2023;29(7):509–16.CrossRefPubMed Singh AK, Singh A, Singh R. Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials. Endocr Pract. 2023;29(7):509–16.CrossRefPubMed
8.
go back to reference ElSayed NA, Aleppo G, Aroda VR, et al. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140–57.CrossRefPubMed ElSayed NA, Aleppo G, Aroda VR, et al. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140–57.CrossRefPubMed
9.
go back to reference Blonde L, Umpierrez GE, Reddy SS, et al. American association of clinical endocrinology clinical practice guideline: Developing a diabetes mellitus comprehensive care plan-2022 update. Endocr Pract. 2022;28(10):923–1049.CrossRefPubMedPubMedCentral Blonde L, Umpierrez GE, Reddy SS, et al. American association of clinical endocrinology clinical practice guideline: Developing a diabetes mellitus comprehensive care plan-2022 update. Endocr Pract. 2022;28(10):923–1049.CrossRefPubMedPubMedCentral
10.
go back to reference Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study objective. Diabetes Care. 2014;37:740–50.CrossRefPubMed Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study objective. Diabetes Care. 2014;37:740–50.CrossRefPubMed
11.
go back to reference Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38:376–83.CrossRefPubMed Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38:376–83.CrossRefPubMed
12.
go back to reference Matthaei S, Catrinoiu D, Celinski A, et al. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes. Diabetes Care. 2015;38:2018–24.CrossRefPubMed Matthaei S, Catrinoiu D, Celinski A, et al. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes. Diabetes Care. 2015;38:2018–24.CrossRefPubMed
13.
go back to reference Mathieu C, Ranetti AE, Li D, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015;38:2009–17.CrossRefPubMed Mathieu C, Ranetti AE, Li D, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015;38:2009–17.CrossRefPubMed
14.
go back to reference Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38(3):394–402.CrossRefPubMed Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38(3):394–402.CrossRefPubMed
15.
go back to reference DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384–93.CrossRefPubMed DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384–93.CrossRefPubMed
16.
go back to reference Singh AK, Singh R. Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence. Indian J Endocrinol Metab. 2016;20(2):245–53.CrossRefPubMedPubMedCentral Singh AK, Singh R. Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence. Indian J Endocrinol Metab. 2016;20(2):245–53.CrossRefPubMedPubMedCentral
17.
go back to reference Min SH, Yoon JH, Moon SJ, et al. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis. Sci Rep. 2018;8:4466.ADSCrossRefPubMedPubMedCentral Min SH, Yoon JH, Moon SJ, et al. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis. Sci Rep. 2018;8:4466.ADSCrossRefPubMedPubMedCentral
18.
go back to reference Chadha M, Das AK, Deb P, Gangopadhyay KK, et al. Expert opinion: optimum clinical approach to combination-use of SGLT2i + DPP4i in the Indian diabetes setting. Diabetes Ther. 2022;13(5):1097–114.CrossRefPubMedPubMedCentral Chadha M, Das AK, Deb P, Gangopadhyay KK, et al. Expert opinion: optimum clinical approach to combination-use of SGLT2i + DPP4i in the Indian diabetes setting. Diabetes Ther. 2022;13(5):1097–114.CrossRefPubMedPubMedCentral
20.
go back to reference Morga A, Latimer NR, Scott M, et al. Is intention to treat still the gold standard or should health technology assessment agencies embrace a broader estimands framework: Insights and perspectives from the National Institute for health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) addendum. Value Health. 2023;26:234–42.CrossRefPubMed Morga A, Latimer NR, Scott M, et al. Is intention to treat still the gold standard or should health technology assessment agencies embrace a broader estimands framework: Insights and perspectives from the National Institute for health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) addendum. Value Health. 2023;26:234–42.CrossRefPubMed
21.
go back to reference Declaration of Helsinki (Ethical principles for medical research involving human subjects, revised by the 64th WMA General Assembly). Brazil: 2013. Declaration of Helsinki (Ethical principles for medical research involving human subjects, revised by the 64th WMA General Assembly). Brazil: 2013.
22.
go back to reference New Drugs and Clinical Trial Rules, 2019 of CDSCO (Central Drugs Standard Control organization), Ministry of health and family welfare, Government of India. New Drugs and Clinical Trial Rules, 2019 of CDSCO (Central Drugs Standard Control organization), Ministry of health and family welfare, Government of India.
23.
go back to reference Bell DS. Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab. 2013;15:291–300.CrossRefPubMed Bell DS. Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab. 2013;15:291–300.CrossRefPubMed
24.
go back to reference Rombopoulos G, Hatzikou M, Athanasiadis A, et al. Treatment compliance with fixed-dose combination of vildagliptin/metformin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: A 24-week observational study. Int J Endocrinol. 2015;2015:251485.CrossRefPubMedPubMedCentral Rombopoulos G, Hatzikou M, Athanasiadis A, et al. Treatment compliance with fixed-dose combination of vildagliptin/metformin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: A 24-week observational study. Int J Endocrinol. 2015;2015:251485.CrossRefPubMedPubMedCentral
25.
Metadata
Title
A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial
Authors
Awadhesh Kumar Singh
Rakesh Sahay
Navneet Gil
Sudhir Tripathi
Vipul Khandelwal
Indraneel Basu
Jayashree Shembalkar
Manoj Kumar Srivastava
Girish Bhatia
Vaishali Pathak
Amol Dange
Mayura Chaudhri
Arindam Naskar
Ashish Mondal
Pawan Gangwal
Surendra Kumar
Deepak Kumar
Yandrapati gnana sundara Raju
Sanket Sorate
Onkar Gavli
Sunita Kumbalkar
Deepak Varade
Harshal Chaudhari
Durga Prasad
Manoj Patil
Nikhil Bhagwat
Rohit Agarwal
Arun Pandey
Soumya Ghosh
Shubhashree Patil
Vishal Kini
Akhilesh Sharma
Mayur Mayabhate
Roshan Pawar
Aashish Rajput
Vinakaya Shahavi
Publication date
17-02-2024
Publisher
Springer India
Published in
International Journal of Diabetes in Developing Countries / Issue 1/2024
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-024-01321-9

Other articles of this Issue 1/2024

International Journal of Diabetes in Developing Countries 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine